Communiqués GlucoTrack, Inc.

Actions

GCTK

US45824Q8877

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:59:53 01/10/2026			Varia. 5j.	Varia. 1 janv.
1,410 ^USD	-14,02%		-46,51%	-97,62%

18/09	Glucotrack, Inc. annonce la démission de Paul V. Goode du conseil d'administration, effective au 14 septembre 2026	CI
18/09	Lokahi Therapeutics, Inc. et l'Université de l'Alabama poursuivent leur collaboration au sein de la division ai² Pipeline	CI

Communiqués

30/09	Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14	BU
28/09	Lokahi Therapeutics Expands ai2 Pipeline Program through Collaboration with Pepperdine E2B	AQ
25/09	Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™	BU
24/09	Lokahi Therapeutics and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai-2 Platform Growth and Clinical Development Priorities	AQ
24/09	Glucotrack, Inc. Announces Pricing of $3 Million Public Offering	BU
23/09	Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform	BU
23/09	Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities	BU
18/09	Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent	BU
11/09	Glucotrack Announces $11.5 Million Financing	BU
08/09	Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions	BU
03/09	Lokahi Therapeutics Expands ai-2 Futures Lab Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business	AQ
02/09	Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business	BU
27/08	Glucotrack, Inc. Announces Reverse Stock Split	BU
26/08	Lokahi Therapeutics Initiates Clinical Trial Manufacturing for LT-100	AQ
25/08	Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100	BU
24/08	Lokahi Therapeutics Expands ai-2 Futures Lab Asset Origination Network Through Continued Collaboration with the University of Georgia	AQ
21/08	Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia	BU
17/08	Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation	BU
06/08	E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack	AQ
05/08	Glucotrack Announces $5.5 Million Financing	BU
03/08	Lokahi Therapeutics ai-2 Futures Lab Changes How Biopharma Builds a Pipeline	AQ
31/07	CORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline	BU
30/07	Lokahi Therapeutics Advances LT-100 Development Strategy toward Single-Injection Administration	AQ
29/07	Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration	BU
17/07	E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing	AQ